Today: 13 November 2025
Subscribe
Browse Category

Analyst Ratings News 21 October 2025 - 13 November 2025

BigBear.ai (BBAI) Stock’s Wild Ride: Palantir Shock, Defense AI Deals & 2025 Outlook

BigBear.ai (BBAI) soars on Nov. 13 as two-day AI‑defense rally extends; fresh analyst note trims price target despite momentum

Updated November 13, 2025 — Midday Summary: BigBear.ai stock is rallying again today, extending gains kicked off earlier this week by Q3 results and a $250 million deal to buy Ask Sage. As of 12:04 UTC, shares trade at $7.17, up about 18.4% from yesterday’s close. At the same time, a new note this morning trimmed BBAI’s price target, underscoring how divided the Street remains on the name. What’s new today (Nov. 13, 2025) Why the stock is moving 1) M&A catalyst — $250M Ask Sage deal.On Monday after the bell, BigBear.ai announced a definitive agreement to acquire Ask Sage—a
13 November 2025
 ·  ·  ·  ·  · 
AB InBev (BUD) Today — Nov. 11, 2025: Morgan Stanley Trims Price Target as Buyback Progresses; DZ Bank Reiterates ‘Buy’ and Valuation Debates Heat Up

AB InBev (BUD) Today — Nov. 11, 2025: Morgan Stanley Trims Price Target as Buyback Progresses; DZ Bank Reiterates ‘Buy’ and Valuation Debates Heat Up

Updated: November 11, 2025Tickers: NYSE: BUD · Euronext Brussels: ABI Key points What changed today Morgan Stanley trims but stays bullish. In a Tuesday note, Morgan Stanley reduced its AB InBev price target to $79while maintaining Overweight. The team cut organic volume expectations for FY25 and grew more cautious for early 2026, but nudged FY25 organic EBITDA growth a touch higher after Q3. Higher finance costs (including BRL hedging) and lower volumes drive the model changes; even so, the bank said its EPS forecasts remain above Visible Alpha consensus. ( Investing.com) Share buyback momentum. After unveiling a $6bn program alongside Q3 results in late October, AB
11 November 2025
 ·  ·  ·  · 
PubMatic (PUBM) Soars on Q3 Beat as Analysts Hike Targets to $20; AI & CTV Momentum in Focus — Nov. 11, 2025

PubMatic (PUBM) Soars on Q3 Beat as Analysts Hike Targets to $20; AI & CTV Momentum in Focus — Nov. 11, 2025

As of 15:42 UTC on Nov. 11, PubMatic shares last traded around $10.40, up sharply intraday following last night’s earnings and a flurry of analyst target increases. Why PUBM is moving today Key numbers & operating highlights Third quarter (ended Sept. 30, 2025): Growth drivers called out by management: Q4 2025 outlook (company guidance) PubMatic guided Q4 revenue to $73M–$77M and adjusted EBITDA to $19M–$21M (~27% margin at the midpoint). Guidance factors in FX headwinds and notes an impact from one top DSP buyer. Nasdaq What Wall Street said today Strategy check: CTV, SPO, and AI Management emphasized three pillars:
11 November 2025
 ·  ·  ·  ·  · 
Siemens Energy Hits Record Highs as Analysts Boost Targets: How AI, Grid Demand and a Wind Turnaround Drive the Stock Rally

Siemens Energy Soars After Jefferies Upgrade to €134; Commerzbank Jumps on Deutsche Bank ‘Buy’ as DAX Closes +1.65% (Nov 10, 2025)

Published: Monday, 10 November 2025 German equities rallied to start the week, led by Siemens Energy and Commerzbank after fresh analyst upgrades propelled both stocks to the top of the DAX. The benchmark index finished up 1.65% at 23,959.99, aided by broader risk-on sentiment as investors bet on progress in the U.S. budget impasse. Investing.com Deutsch Key takeaways Siemens Energy leads after Jefferies calls for €134 target Siemens Energy (Xetra: ENR) rallied after Jefferies shifted its rating to “Buy” and more than doubled its price target to €134. Analyst Lucas Ferhani argued the company’s product portfolio is positioned against the
10 November 2025
 ·  ·  ·  · 
Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. (NASDAQ: QLYS) is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS forecasts, keeping the cybersecurity name on radar for Google News and Discover readers tracking post‑earnings momentum. The shares are trading around the $150 mark. MarketBeat+1 What’s new today (Nov 8, 2025) Bottom line for Nov 8: The weekend headlines extend a favorable post‑earnings narrative built on raised guidance and improving profitability metrics. Earnings recap: Q3 FY2025 at a glance Qualys
8 November 2025
 ·  ·  ·  ·  · 
Breaking: Eos Energy & MN8 Secure Huge 750 MWh U.S. Battery Storage Deal – Are Stocks Set to Skyrocket?

Eos Energy (EOSE) News Today: Price Target Uplift, Fresh Downgrade, and 70% Warrant Surge — What’s Moving the Stock (Nov 8, 2025)

Updated: November 8, 2025 Key takeaways What’s new today (Nov. 8, 2025) Downgrade lands after the run-up. MarketBeat carried an alert that Wall Street Zen cut EOSE to “Sell” early Saturday, noting the stock’s sharp appreciation and summarizing the existing split in coverage (a mix of Buy/Hold/Sell ratings and an average target near the low teens). While not a bulge-bracket call, the downgrade adds a counterweight to bullish revisions that followed earnings. MarketBeat Fresh transcript color: cash, guidance, and warrants. A newly posted Q3 2025 earnings call transcript highlights management’s stance that execution into Q4 supports the low end of
8 November 2025
 ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth (UNH) Premarket: Analysts Bullish on Comeback Despite 2025 Woes – What to Watch Nov. 3, 2025

UnitedHealth’s volatile 2025 has made UNH a headline story heading into Nov. 3 trading. After a surprise earnings miss in Q1 and a CEO shakeup this spring, UNH plunged to four-year lows. In late Oct. the turnaround narrative got a boost: Q3 beat estimates and management raised guidance gurufocus.com gurufocus.com. CEO Stephen Hemsley (back at the helm) told investors he’s confident “we will return to solid earnings growth next year” thanks to “operational rigor and more prudent pricing” reuters.com. Guggenheim and Reuters note Hemsley’s comeback has reassured investors and even prompted Buffett to buy in reuters.com reuters.com. Market analysts are increasingly
2 November 2025
 ·  ·  ·  · 
Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Visa Stock Jumps on Earnings Beat and Dividend Hike – Analysts Bullish on $400 Target

Visa’s Stock Rallies After Earnings and Dividend Hike Visa’s latest earnings report delivered plenty for investors to cheer. The company’s fiscal fourth-quarter results (for the quarter ended September 30, 2025) beat expectations on both the top and bottom line. Net revenues grew 12% year-over-year to $10.72 billion, slightly above consensus forecasts around $10.6 billion timesunion.com. Adjusted earnings came in at $2.98 per share, just topping analysts’ $2.97 estimate timesunion.com and up from $2.71 a year ago. This strong finish to the year reflected healthy consumer payment volumes and improved cross-border travel spending, even as the company had maintained cautious guidance in prior
28 October 2025
 ·  ·  ·  ·  · 
Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 marketbeat.com (from $2.92 prior close), and on Oct. 24 it spiked another ~18%, trading near $3.79 (from $3.20 close on Oct. 23) reuters.com. According to Reuters data, that surge propelled CLOV close to its 52-week high (~$4.87) and far above its recent 50‑day moving average (around $2.82) marketbeat.com. The 200-day average (~$3.02) was also eclipsed, signaling strong upward momentum marketbeat.com. This rally has come on unusually heavy volume (15+ million shares traded on Oct. 24 vs. a 3‑month average
24 October 2025
 ·  ·  ·  ·  · 
Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

Stock Rallies on Upbeat Sentiment On Oct. 21, 2025, Sunrun (Nasdaq: RUN) traded around $20.50, up about 5% intraday reuters.com. This surge followed news that Wall Street’s Citigroup had upgraded Sunrun to “Buy” with a $26 price target marketbeat.com. The stock’s rally pushed it above the consensus 12-month analyst target (~$20) ts2.tech. In fact, RUN hit a new 12-month high (~$20.25) on Oct. 7 markets.financialcontent.com, as investors cheered its improving fundamentals and solar incentives. Over the year, Sunrun has been on a tear. Earlier in 2025, the shares languished near multi-year lows (around $5.38), but rallied into the teens after
21 October 2025
 ·  ·  ·  ·  · 
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s close marketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-date marketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech
21 October 2025
 ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop